EUVIMEDEUVIMED entdecken
Open Access

The Phosphatidylinositol 3-Kinase (PI3K) Inhibitor Inavolisib Has Breast-cancer Synergy Combined With Recombinant Methioninase But Not on Normal Cells

Jinsoo Kim, Qinghong Han, Shukuan Li, Yuta Miyashi, Tomoyuki Ishiguro, Michael Bouvet, Robert M Hoffman

In Vivo · 2026

DOI: 10.21873/invivo.14420 ↗

Kurz gefasst

Fachartikel in der Zeitschrift In Vivo, 2026. Verfasst von Jinsoo Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: AntiCancer Inc., San Diego, CA, U.S.A. Hauptthemen laut MEDLINE: Breast Neoplasms, Carbon-Sulfur Lyases, Phosphoinositide-3 Kinase Inhibitors. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCarbon-Sulfur LyasesPhosphoinositide-3 Kinase InhibitorsHumansFemaleDrug SynergismMCF-7 CellsCell SurvivalFibroblastsRecombinant ProteinsCell ProliferationCell Line, TumorAntineoplastic AgentsSignal TransductionImidazolesIndazolesOxazolesSulfonamides

Stichwörter der Autor:innen

Hoffman effectHs-27 normal fibroblastsInavolisibMCF-7PI3K inhibitorbreast-cancer cellsmethionine addictionrecombinant methioninasesynergy

Substanzen

Carbon-Sulfur LyasesL-methionine gamma-lyasePhosphoinositide-3 Kinase InhibitorsRecombinant Proteins2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidineAntineoplastic AgentsinavolisibImidazolesIndazolesOxazoles

Autor:innen und Institutionen

  • AntiCancer Inc., San Diego, CA, U.S.A.
  • Department of Surgery, University of California, San Diego, CA, U.S.A.
  • Department of Surgery, Chungnam National University College of Medicine, Daejeon, Republic of Korea.
  • AntiCancer Inc., San Diego, CA, U.S.A.; all@anticancer.com.

Zitieren

APA

Kim, J., Han, Q., Li, S., Miyashi, Y., Ishiguro, T., Bouvet, M., & Hoffman, R. M. (2026). The Phosphatidylinositol 3-Kinase (PI3K) Inhibitor Inavolisib Has Breast-cancer Synergy Combined With Recombinant Methioninase But Not on Normal Cells. In Vivo. https://doi.org/10.21873/invivo.14420

Vancouver

Kim J, Han Q, Li S, Miyashi Y, Ishiguro T, Bouvet M, et al. The Phosphatidylinositol 3-Kinase (PI3K) Inhibitor Inavolisib Has Breast-cancer Synergy Combined With Recombinant Methioninase But Not on Normal Cells. In Vivo. 2026. doi:10.21873/invivo.14420

BibTeX
@article{Kim2026,
  author = {Kim, Jinsoo and Han, Qinghong and Li, Shukuan and Miyashi, Yuta and Ishiguro, Tomoyuki and Bouvet, Michael and Hoffman, Robert M},
  title = {The Phosphatidylinositol 3-Kinase (PI3K) Inhibitor Inavolisib Has Breast-cancer Synergy Combined With Recombinant Methioninase But Not on Normal Cells},
  journal = {In Vivo},
  year = {2026},
  doi = {10.21873/invivo.14420}
}
Kostenlos starten →